Clicky

Genor Biopharma Holdings Ltd(6998)

Description: Genor Biopharma Holdings Limited, a biopharmaceutical company, focuses on developing and commercializing oncology and autoimmune drugs in China and internationally. The company's principal drug candidates include GB242, an infliximab (Remicade) biosimilar for the treatment of rheumatoid arthritis, ankylosing spondylitis, psoriasis, adult ulcerative colitis, adult and pediatric crohn's disease, and fistulising crohn's disease; GB491 (lerociclib), an oral CDK4/6 inhibitor for treating hormone receptor-positive (HR+)/HER2- breast cancer and is under Phase III clinical trials; and GB492, a stimulator of interferon genes (STING) agonist expected to exert synergistic effects in combination with GB226 for solid tumors and is under Phase 1/2 clinical trial. Further, it develops GB221, a herceptin (trastuzumab)-mimic HER2 monoclonal antibody (mAb) drug candidate; geptanolimab (GB226), a novel PD-1 mAb drug candidate; GB223, a receptor activator of nuclear factor-B Ligand (RANKL) mAb drug candidate, which is under Phase I clinical trial; and GB261 to treat B-cell non-Hodgkin Lymphoma and is under Phase I Clinical trials. In addition, the company's product candidates under clinical trials include GB262, GB264, GB265, and GB 266 for the treatment of cancer. Genor Biopharma Holdings Limited was formerly known as JHBP (CY) Holdings Limited and changed its name to Genor Biopharma Holdings Limited in June 2021. The company was founded in 2007 and is headquartered in Shanghai, China.


Keywords: Medicine Biotechnology Cancer Biopharmaceutical Life Sciences Immunology Solid Tumors Treatment Of Cancer Monoclonal Antibodies Rheumatoid Arthritis Psoriasis Specialty Drugs Crohn's Disease Her2/Neu Spondylitis Trastuzumab Infliximab Her2 Breast Cancer

Home Page: www.genorbio.com

Building 3
Shanghai, 201203
China
Phone: 86 21 6169 0700


Officers

Name Title
Dr. Feng Guo Ph.D. CEO & Chairman
Mr. Chengyi Weng VP of Fin.
Qibin Liang Chief Technology Officer
Dr. Shuhua Han Ph.D. Chief Scientist
Ms. Xiaojing Zhu VP of Compliance & Admin.
Mr. Tong Li Chief Medical Officer
Cheery Chen Chief Regulatory Officer
Mr. Tak Wai Ip Company Sec.
Mr. Jun Lin VP of Quality Analysis
Ms. Yao Chen VP of Regulatory Affairs

Exchange: HK

Country: HK

Currency: Hong Kong Dollar (HK$)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 0.6163
Price-to-Sales TTM: 466.5474
IPO Date:
Fiscal Year End: December
Full Time Employees: 452
Back to stocks